Design and Mechanism of GABA Aminotransferase Inactivators. Treatments for Epilepsies and Addictions

Overview

Journal Chem Rev

Publisher American Chemical Society

Specialty Chemistry

Date 2018 Mar 24

PMID 29569907

Citations 30

Authors

Richard B Silverman

Affiliations

Soon will be listed here.

Abstract

When the brain concentration of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) diminishes below a threshold level, the excess neuronal excitation can lead to convulsions. This imbalance in neurotransmission can be corrected by inhibition of the enzyme γ-aminobutyric acid aminotransferase (GABA-AT), which catalyzes the conversion of GABA to the excitatory neurotransmitter l-glutamic acid. It also has been found that raising GABA levels can antagonize the rapid elevation and release of dopamine in the nucleus accumbens, which is responsible for the reward response in addiction. Therefore, the design of new inhibitors of GABA-AT, which increases brain GABA levels, is an important approach to new treatments for epilepsy and addiction. This review summarizes findings over the last 40 or so years of mechanism-based inactivators (unreactive compounds that require the target enzyme to catalyze their conversion to the inactivating species, which inactivate the enzyme prior to their release) of GABA-AT with emphasis on their catalytic mechanisms of inactivation, presented according to organic chemical mechanism, with minimal pharmacology, except where important for activity in epilepsy and addiction. Patents, abstracts, and conference proceedings are not covered in this review. The inactivation mechanisms described here can be applied to the inactivations of a wide variety of unrelated enzymes.

Citing Articles

L. aqueous extract protects mice against pilocarpine-picrotoxin kindling-induced temporal lobe epilepsy, oxidative stress, and alteration in GABAergic/cholinergic pathways and BDNF expression.

Mambou H, Pale S, Bopda O, Jugha V, Musa N, Ojongnkpot T Front Pharmacol. 2025; 15:1301002.

PMID: 39996118 PMC: 11848678. DOI: 10.3389/fphar.2024.1301002.

Suppressing astrocytic GABA transaminase enhances tonic inhibition and weakens hippocampal spatial memory.

Park M, Lim J, Kim D, Lee W, Yoon B, Lee C Exp Mol Med. 2025; 57(2):379-389.

PMID: 39894826 PMC: 11873293. DOI: 10.1038/s12276-025-01398-0.

Low-frequency stimulation of corpus callosum suppresses epileptiform activity in the cortex through γ-aminobutyric acid type B receptor and slow afterhyperpolarization-mediated reduction in tissue excitability.

Pakalapati N, Chiang C, Durand D Epilepsia. 2024; 65(12):3689-3702.

PMID: 39425912 PMC: 11647442. DOI: 10.1111/epi.18135.

New epilepsy therapies in development.

Klein P, Kaminski R, Koepp M, Loscher W Nat Rev Drug Discov. 2024; 23(9):682-708.

PMID: 39039153 DOI: 10.1038/s41573-024-00981-w.

Pathogenesis, diagnosis, and treatment of epilepsy: electromagnetic stimulation-mediated neuromodulation therapy and new technologies.

Jiao D, Xu L, Gu Z, Yan H, Shen D, Gu X Neural Regen Res. 2024; 20(4):917-935.

PMID: 38989927 PMC: 11438347. DOI: 10.4103/NRR.NRR-D-23-01444.

References

Kobayashi K, Miyazawa S, Endo A . Isolation and inhibitory activity of gabaculine, a new potent inhibitor of gamma-aminobutyrate aminotransferase produced by a Streptomyces. FEBS Lett. 1977; 76(2):207-10. DOI: 10.1016/0014-5793(77)80153-1. View

Ravasz D, Kacso G, Fodor V, Horvath K, Adam-Vizi V, Chinopoulos C . Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation. Neurochem Int. 2017; 109:41-53. DOI: 10.1016/j.neuint.2017.03.008. View

Jung M, Heydt J, Casara P . Gamma-allenyl GABA, a new inhibitor of 4-amino butyrate amino transferase. Comparison with other inhibitors of this enzyme. Biochem Pharmacol. 1984; 33(22):3717-20. DOI: 10.1016/0006-2952(84)90164-3. View

Mehta P, Hale T, Christen P . Aminotransferases: demonstration of homology and division into evolutionary subgroups. Eur J Biochem. 1993; 214(2):549-61. DOI: 10.1111/j.1432-1033.1993.tb17953.x. View

Huang H, Hah J, Silverman R . Mechanism of nitric oxide synthase. Evidence that direct hydrogen atom abstraction from the O-H bond of NG-hydroxyarginine is not relevant to the mechanism. J Am Chem Soc. 2001; 123(11):2674-6. DOI: 10.1021/ja005900u. View

Rando R . Irreversible inhibition of aspartate aminotransferase by 2-amino-3-butenoic acid. Biochemistry. 1974; 13(19):3859-63. DOI: 10.1021/bi00716a006. View

Maker H, Weiss C, WEISSBARTH S, SILIDES D, Whetsell W . Regional activities of metabolic enzymes and glutamate decarboxylase in human brain. Ann Neurol. 1981; 10(4):377-83. DOI: 10.1002/ana.410100410. View

Rando R, Bangerter F . The irreversible inhibition of mouse brain gamma-aminobutyric acid (GABA)-alpha-ketoglutaric acid transaminase by gabaculine. J Am Chem Soc. 1976; 98(21):6762-4. DOI: 10.1021/ja00437a090. View

CHURCHICH J, Moses U . 4-Aminobutyrate aminotransferase. The presence of nonequivalent binding sites. J Biol Chem. 1981; 256(3):1101-4. View

10.

Juncosa J, Takaya K, Le H, Moschitto M, Weerawarna P, Mascarenhas R . Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction. J Am Chem Soc. 2018; 140(6):2151-2164. PMC: 5812813. DOI: 10.1021/jacs.7b10965. View

11.

Jung M, Lippert B, Metcalf B, Schechter P, Bohlen P, SJOERDSMA A . The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gammma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo. J Neurochem. 1977; 28(4):717-23. DOI: 10.1111/j.1471-4159.1977.tb10618.x. View

12.

Metcalf B, Jung M . Molecular basis for the irreversible inhibition of 4-aminobutyric acid:2-oxoglutarate and L-ornithine:2-oxoacid aminotransferases by 3-amino-1,5-cyclohexadienyl carboxylic acid (isogabaculline). Mol Pharmacol. 1979; 16(2):539-45. View

13.

Park M, Igarashi K . Polyamines and their metabolites as diagnostic markers of human diseases. Biomol Ther (Seoul). 2013; 21(1):1-9. PMC: 3762300. DOI: 10.4062/biomolther.2012.097. View

14.

Le H, Hawker D, Wu R, Doud E, Widom J, Sanishvili R . Design and mechanism of tetrahydrothiophene-based γ-aminobutyric acid aminotransferase inactivators. J Am Chem Soc. 2015; 137(13):4525-33. PMC: 4390550. DOI: 10.1021/jacs.5b01155. View

15.

Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O . A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms. Epilepsy Behav Case Rep. 2016; 6:67-9. PMC: 5024311. DOI: 10.1016/j.ebcr.2016.08.002. View

16.

John R, Jones E, Fowler L . Enzyme-induced inactivation of transminases by acetylenic and vinyl analogues of 4-aminobutyrate. Biochem J. 1979; 177(2):721-8. PMC: 1186424. DOI: 10.1042/bj1770721. View

17.

Solas M, Puerta E, Ramirez M . Treatment Options in Alzheimer´s Disease: The GABA Story. Curr Pharm Des. 2015; 21(34):4960-71. DOI: 10.2174/1381612821666150914121149. View

18.

de Boer H, Mula M, Sander J . The global burden and stigma of epilepsy. Epilepsy Behav. 2008; 12(4):540-6. DOI: 10.1016/j.yebeh.2007.12.019. View

19.

Danzin C, Claverie N, Jung M . Stereochemistry of the inactivation of 4-aminobutyrate: 2-oxoglutarate aminotransferase and L-glutamate 1-carboxylase by 4-aminohex-5-ynoic acid enantiomers. Biochem Pharmacol. 1984; 33(11):1741-6. DOI: 10.1016/0006-2952(84)90343-5. View

20.

Schiffer W, Marsteller D, Dewey S . Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl). 2003; 168(3):339-43. DOI: 10.1007/s00213-003-1446-6. View